Vaxcyte Inc (NQ: PCVX )
37.48 +1.21 (+3.34%) Streaming Delayed Price Updated: 4:00 PM EDT, Mar 31, 2023 Add to My Watchlist
Headline News about Vaxcyte Inc
Preview: Vaxcyte's Earnings
February 24, 2023
Expert Ratings for Vaxcyte
January 03, 2023
Benzinga's Top Ratings Upgrades, Downgrades For December 16, 2022
December 16, 2022
Benzinga's Top Ratings Upgrades, Downgrades For December 15, 2022
December 15, 2022
Benzinga's Top Ratings Upgrades, Downgrades For November 17, 2022
November 17, 2022
Why Vaxcyte Shares Are Trading Sharply Higher? Here Are 63 Stocks Moving In Monday's Mid-Day Session
October 24, 2022
Gainers Vaxcyte, Inc. (NASDAQ: PCVX) shares jumped 65% to $33.96 after the company announced positive topline results from the Phase 1/2 clinical proof-of-concept study evaluating the safety,...
Vaxcyte Completes Enrolment In Mid-Stage Pneumococcal Disease Study, Sees Top-line Data In H1 2013
September 06, 2022
Vaxcyte (NASDAQ: PCVX) has completed patient enrollment in the Phase 2 study evaluating VAX-24 in healthy adults 65 years of age and older. VAX-24 is its lead, 24-valent pneumococcal conjugate vaccine...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following